Stevanato Group is on a strong upward trajectory in Q2 2026, with revenue soaring 8% YoY fueled by biologics and diagnostics—especially their high-value solutions driving 16% growth. They’ve shed Balda C. Brewer to sharpen focus on integrated drug delivery, landing major wins like the Alina pen’s EU approval for diabetes and weight management. With injectable biologics booming and pharma demanding end-to-end partners, Stevanato’s full-stack capabilities are hitting the sweet spot. Their new Deora multi-use pen targets strict dosing needs, while Engineering stabilizes thanks to optimization—and U.S./Italy expansion is poised to scale capacity. This is a company betting big on high-margin, differentiated tech, building sustainable value one innovation at a time.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
